[Kalpana]

MedImmune LLC, is a US based biotechnology enterprise, acquired by AstraZeneca in 2007. It has its headquarters in Gaithersburg, Maryland. It was established by Wayne T. Hockmeyer as Molecular vaccines Inc. in 1988 and was changed to MedImmune in 1990. Company develops and manufactures immunological research based products, its most famous drugs are Synagis and FluMist.

In this forum we will discuss about its latest technologies, developments, recognitions and vacancies.

• AstraZeneca selects Cambridge UK for a new location for MedImmune
  

AstraZeneca small molecules and MedImmune's biologic research together are going to establish a center in Cambridge Biomedical Campus. An investment of 330 million pounds has been put up for a high-tech built-in facility for advanced research. The proposed destination will be all set to shine by 2016. Further company plans to put up its specialized R&D centers in UK, US and Sweden.

• MedImmune acquires Alphacore pharma
  

AstraZeneca's biological arm MedImmune acquired a newbie Alphacore pharma an Ann Arbor, Michigan based company focused on the development on ACP-501, a recombinant human lecithin-cholesterol acyltransferase (LCAT) enzyme. Its a key component in the reverse cholesterol transport system, which plays a major role in removal of cholesterol from the body.

• MedImmune won equipment innovation award
  

MedImmune won equipment innovation award for its UK Automation Upgrade Project in Speke, Liverpool, UK. MedImmune team used system design engineering for automation of full manufacturing train with each specialized discreet step. This extraordinary automation resulted into 15% increase in yield, 25% reduction in manual labor, 8% reduction in rejects or failures, and a decrease in waste at every stage of the process. This has a landmark in the automation industry.

• MedImmune vacancies
  

Check out the MedImmune career website for extensive job offers in the field of biochemistry, molecular biology, bioprocess engineering and more.




Lets wait for another big news by MedImmune.